Subscribe
hailshadow-istockphoto-com
Hailshadow / iStockphoto.com
26 October 2017Americas

Public interest group challenges ‘unmerited’ Gilead patents

Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
Non-profit asks US government to take Gilead hepatitis C patent
20 March 2018   A non-profit organisation has requested that the US government take the title of a patent covering Gilead’s sofosbuvir-based hepatitis C medicine.
Americas
Non-profit group continues battle against Gilead patents
8 December 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
Non-profit asks US government to take Gilead hepatitis C patent
20 March 2018   A non-profit organisation has requested that the US government take the title of a patent covering Gilead’s sofosbuvir-based hepatitis C medicine.
Americas
Non-profit group continues battle against Gilead patents
8 December 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.

More on this story

Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
Non-profit asks US government to take Gilead hepatitis C patent
20 March 2018   A non-profit organisation has requested that the US government take the title of a patent covering Gilead’s sofosbuvir-based hepatitis C medicine.
Americas
Non-profit group continues battle against Gilead patents
8 December 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB